Tharimmune Stock Performance
| THAR Stock | 3.59 0.36 11.15% |
On a scale of 0 to 100, Tharimmune holds a performance score of 6. The entity has a beta of 0.84, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tharimmune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Tharimmune is expected to be smaller as well. Please check Tharimmune's value at risk, and the relationship between the jensen alpha and skewness , to make a quick decision on whether Tharimmune's existing price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Tharimmune are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Tharimmune reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 11.15 | Five Day Return 18.87 | Year To Date Return 6.21 | Ten Year Return (99.72) | All Time Return (99.72) |
Last Split Factor 1:15 | Last Split Date 2024-05-28 |
1 | Insider Trading | 10/29/2025 |
2 | Tharimmune Stock Price Down 5.9 percent - Whats Next - MarketBeat | 12/19/2025 |
3 | Tharimmune prices 55M registered offering | 01/20/2026 |
4 | Tharimmune prices 55M registered offering - MSN | 01/21/2026 |
5 | Tharimmune Announces Expanded Role as Super Validator on Canton Network | 01/26/2026 |
| Begin Period Cash Flow | 10.9 M | |
| Free Cash Flow | -10.9 M |
Tharimmune | Build AI portfolio with Tharimmune Stock |
Tharimmune Relative Risk vs. Return Landscape
If you would invest 297.00 in Tharimmune on October 30, 2025 and sell it today you would earn a total of 62.00 from holding Tharimmune or generate 20.88% return on investment over 90 days. Tharimmune is currently generating 0.5043% in daily expected returns and assumes 6.2694% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Tharimmune, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tharimmune Target Price Odds to finish over Current Price
The tendency of Tharimmune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.59 | 90 days | 3.59 | nearly 4.48 |
Based on a normal probability distribution, the odds of Tharimmune to move above the current price in 90 days from now is nearly 4.48 (This Tharimmune probability density function shows the probability of Tharimmune Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Tharimmune has a beta of 0.84. This usually implies as returns on the market go up, Tharimmune average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Tharimmune will be expected to be much smaller as well. Additionally Tharimmune has an alpha of 0.5442, implying that it can generate a 0.54 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Tharimmune Price Density |
| Price |
Predictive Modules for Tharimmune
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tharimmune. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tharimmune Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Tharimmune is not an exception. The market had few large corrections towards the Tharimmune's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tharimmune, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tharimmune within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.54 | |
β | Beta against Dow Jones | 0.84 | |
σ | Overall volatility | 0.43 | |
Ir | Information ratio | 0.09 |
Tharimmune Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tharimmune for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tharimmune can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tharimmune is way too risky over 90 days horizon | |
| Tharimmune appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (12.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tharimmune generates negative cash flow from operations | |
| About 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from prnewswire.com: Tharimmune Announces Expanded Role as Super Validator on Canton Network |
Tharimmune Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tharimmune Stock often depends not only on the future outlook of the current and potential Tharimmune's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tharimmune's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.3 M | |
| Cash And Short Term Investments | 3.6 M | |
| Shares Float | 28.9 M |
Tharimmune Fundamentals Growth
Tharimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Tharimmune, and Tharimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tharimmune Stock performance.
| Return On Equity | -2.25 | ||||
| Return On Asset | -1.0 | ||||
| Current Valuation | 134.46 M | ||||
| Shares Outstanding | 39.53 M | ||||
| Price To Book | 23.06 X | ||||
| EBITDA | (12.43 M) | ||||
| Net Income | (12.2 M) | ||||
| Total Debt | 2.41 M | ||||
| Book Value Per Share | 0.85 X | ||||
| Cash Flow From Operations | (10.9 M) | ||||
| Earnings Per Share | (3.68) X | ||||
| Market Capitalization | 141.91 M | ||||
| Total Asset | 3.72 M | ||||
| Retained Earnings | (36.9 M) | ||||
| Working Capital | 1.31 M | ||||
About Tharimmune Performance
Assessing Tharimmune's fundamental ratios provides investors with valuable insights into Tharimmune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tharimmune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.95) | (3.10) | |
| Return On Capital Employed | (10.93) | (10.39) | |
| Return On Assets | (2.95) | (3.10) | |
| Return On Equity | (10.73) | (10.19) |
Things to note about Tharimmune performance evaluation
Checking the ongoing alerts about Tharimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tharimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tharimmune is way too risky over 90 days horizon | |
| Tharimmune appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (12.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tharimmune generates negative cash flow from operations | |
| About 29.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from prnewswire.com: Tharimmune Announces Expanded Role as Super Validator on Canton Network |
- Analyzing Tharimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tharimmune's stock is overvalued or undervalued compared to its peers.
- Examining Tharimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tharimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tharimmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tharimmune's stock. These opinions can provide insight into Tharimmune's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tharimmune Stock Analysis
When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.